Big Health

Big Health is a San Francisco-based neurotechnology company specializing in prescription digital therapeutics (PDTs) designed to address mental health conditions at scale. The company's flagship products, Sleepio and Daylight, target insomnia and anxiety respectively, delivering structured, evidence-based cognitive behavioral therapy (CBT) through digital platforms accessible via smartphone or web. These programs are built on the principles of established clinical psychology and neuroscience, translating traditional therapeutic frameworks into scalable, software-driven interventions. By replacing or supplementing pharmacological approaches with clinically validated digital programs, Big Health positions its technology as a meaningful alternative within the broader mental health treatment landscape.

Big Health has secured $75 million in Series C funding, reflecting strong investor confidence in the prescription digital therapeutics market and the company's clinical credibility. Both Sleepio and Daylight have been validated through multiple randomized controlled trials, demonstrating outcomes comparable to traditional in-person therapy and, in some cases, first-line medications. The company distributes its products through employer benefits packages and health plan partnerships, giving it access to large, commercially insured populations and enabling deployment at a scale that traditional care models struggle to achieve. This distribution strategy has positioned Big Health as one of the more commercially mature players in the digital mental health space.

Big Health represents a significant development for the neurotech industry by demonstrating that software alone can produce measurable, clinically meaningful changes in brain-based conditions such as sleep disorders and anxiety. Their work helps establish the regulatory and commercial precedent for prescription digital therapeutics as a legitimate category of neurological intervention, sitting at the intersection of neuroscience, behavioral medicine, and health technology. As mental health infrastructure continues to strain under growing global demand, companies like Big Health offer a scalable, cost-effective model that could fundamentally reshape how neurological and psychiatric conditions are treated. Their progress lends important validation to the broader thesis that technology can intervene directly in the function and behavior of the human brain without pharmacological means.